HaberlerTÜBA-GEBİP ve TESEP Ödülleri için 2018 Yılı Başvuruları Devam Ediyor TÜBA Başkanı Prof. Acar’ın “Yeni Yıl” Mesajı TÜBA Üyelerine “TÜBİTAK Ödülleri” 2017 Yılı “Cumhurbaşkanlığı Kültür ve Sanat Büyük Ödülleri” TÜBA-GEBİP Üyelerine “ODTÜ Prof. Dr. Mustafa N. Parlar Eğitim ve Araştırma Vakfı Ödülü” TÜBA 52.Genel Kurulu Gerçekleştirildi Prof. Arslan’dan “Akademi Ödülü Konferansı” 2017 “TÜBA Ödülleri” Sahiplerini Buldu TÜBA-GEBİP Üyesi Doç. Dr. Karahasanoğlu’na “Georg Forster Araştırma Bursu” Bilim, Sanayi ve Teknoloji Bakanı Dr. Özlü, TÜBA Başkanı Prof. Acar ve TÜBA Akademi Ödülü Sahiplerini Kabul Etti
Significant Success of The Principal Member of TÜBA, Prof. Dr. Gökhan Hotamışlıgil and his team
Tarih: 09 OCAK 2014 Okunma Sayısı: 27649
New researches, led by Gökhan Hotamışlıgil who is the Principal Member of TÜBA in Harvard University Genetics and Complex Diseases Departmant,has revealed a mechanism which plays an important role in destruction of beta cells responsible for producing type 1 insulin in diabetes. Furthermore, researches show that this disease could be avoided by a medicine which is natural and effective enough to stop the destruction, on the other hand, using naturally occuring bile acid introduces a new and effective protection and treatment against type 1 diaebetes.
Prof. Dr. Hotamışlıgil stressed the importance of hard work and said: “The results of this study shows us that diabetes could be avoided just by protecting beta cells even without concerning the immune system, thus a new era opens for treatment of the disease. Our finding mechanism and chemical have the capacity for delaying the occurence of the illness considerably or even destroying it completely for children who are in this phase. Thanks to those found mechanisms, we anticipate that other chemicals will be improved for the same object and alternatives will be reached which people-at-risk need strongly.
On November 13th, 2013, one of the leading science magazines Science TM reported Dr. Gökhan Hotamışlıgil and his team’s study which is supported by Juvenile Diabetes Research Foundation (JDRF).